EUVIMEDEUVIMED entdecken
Crossref

Effect of body mass index on the timing of therapeutic drug monitoring—guided dalbavancin dosing in patients with osteoarticular infections

Dario Cattaneo iD, Marta Fusi, Chiara Mariani, Matteo Passerini, Letizia Scandiffio, Sarah Birindelli iD, Stefania Merli, Riccardo Giorgi, Andrea Gori, Alberto Dolci

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Dario Cattaneo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Clinical Pathology, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Teicoplanin, Anti-Bacterial Agents, Drug Monitoring, Body Mass Index. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: the NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recently, we documented that proactive therapeutic drug monitoring (TDM) allowed the successful individualization of the timing of dalbavancin administration in patients requiring prolonged antibiotic treatment. Here, we aimed to identify variables associated with the timing of TDM-guided dalbavancin dosing in patients who underwent proactive dalbavancin TDM.

Methods

Adult patients who received at least three 1500 mg doses of dalbavancin for osteoarticular infections were included in the study. Univariate and multivariate linear regression analyses were performed, considering the timing of dalbavancin administrations as the dependent variable and clinical features as dependent covariates.

Results

Sixty-three patients [65% male, mean (SD) age 64 ± 16 years] fulfilling the inclusion criteria were included in the study. Patients were given a mean (SD) 6.4 ± 5.0 injections of dalbavancin over a mean (SD) period of 198 ± 213 days. Dalbavancin was administered every 40 ± 7 days (range:16–71 days). By univariate linear regression analyses, patient age (P = 0.002), BMI (P < 0.001), serum albumin (P = 0.011) and the duration of dalbavancin treatment (P = 0.012) was found to be associated with the timing of dalbavancin administration. The BMI was the only variable retained in the final multivariate model (P < 0.001). A highly significant reduction in timing of dalbavancin administration was observed between patients with obesity, overweight and normal weight [mean (SD) 30 ± 7 versus 38 ± 4 versus 43 ± 7 days].

Conclusions

Overweight and obesity significantly impacted on dalbavancin pharmacokinetics in patients with osteoarticular infections requiring prolonged antibiotic treatment. These effects can be handled by proactive TDM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TeicoplaninAnti-Bacterial AgentsDrug MonitoringBody Mass IndexHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overTime Factors

Substanzen

dalbavancinTeicoplaninAnti-Bacterial Agents

Autor:innen und Institutionen

  • Unit of Clinical Pathology, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.
  • Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy.
  • Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Luigi Sacco University Hospital, Milan, Italy.
  • Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

ORCID-Profile: Dario Cattaneo, Sarah Birindelli

Förderung

  • the NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases

Zitieren

APA

Cattaneo, D., Fusi, M., Mariani, C., Passerini, M., Scandiffio, L., Birindelli, S., Merli, S., Giorgi, R., Gori, A., & Dolci, A. (2025). Effect of body mass index on the timing of therapeutic drug monitoring—guided dalbavancin dosing in patients with osteoarticular infections. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf132

Vancouver

Cattaneo D, Fusi M, Mariani C, Passerini M, Scandiffio L, Birindelli S, et al. Effect of body mass index on the timing of therapeutic drug monitoring—guided dalbavancin dosing in patients with osteoarticular infections. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf132

BibTeX
@article{Cattaneo2025,
  author = {Cattaneo, Dario and Fusi, Marta and Mariani, Chiara and Passerini, Matteo and Scandiffio, Letizia and Birindelli, Sarah and Merli, Stefania and Giorgi, Riccardo and Gori, Andrea and Dolci, Alberto},
  title = {Effect of body mass index on the timing of therapeutic drug monitoring—guided dalbavancin dosing in patients with osteoarticular infections},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf132}
}
Kostenlos starten →